40 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
Chung, President and Chief Operating Officer at Sutro. “Sutro’s research innovation represented in STRO-003 illustrates our leadership in ADC design
8-K
EX-99.1
STRO
Sutro Biopharma Inc
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
milestones, Vaxcyte would be obligated to pay Sutro up to an additional $60 million.
Corporate Updates:
Sutro continues to build a world-class leadership
8-K
EX-99.1
STRO
Sutro Biopharma Inc
8 Jan 24
Results of Operations and Financial Condition
7:31am
28
Experienced Leadership Team Lynx Neurex 29 Anne Borgman, MD Chief Medical Officer Venkatesh Srinivasan, PhD Chief Technical Operations Officer
8-K
EX-99.1
7yoh 254re2r
21 Nov 23
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
bnrq m6nry
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-99.1
9p2b67jgpp6r ferel
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
8-K
EX-99.1
fzv48bepa61
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
PRE 14A
ipfs01p
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
vc6bz5vg91
30 Mar 23
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
4:32pm
8-K
EX-99.1
5csa2ksmqnvy2d
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm